Our response to NICE’s decision not to recommend lenacapavir as PrEP
Last Updated:Our response to the National Institute for Health and Care Excellence (NICE) decision not to recommend lenacapavir as PrEP.
Our response to the National Institute for Health and Care Excellence (NICE) decision not to recommend lenacapavir as PrEP.
National AIDS Trust warns UK's 2030 HIV targets are at risk without cross-government action.
Our response to news that Grindr have paid £26m to settle UK lawsuit over allegedly sharing users' HIV status:
Cabotegravir (CAB-LA) will help close the prevention gap for people who face barriers to adhering to oral PrEP.
A statement from National AIDS Trust following reports of potential cuts to PEPFAR funding, which provides treatment and services to millions of people overseas.
Our calls for the new HIV Action Plan for England
Aaron Markwell has produced a new exhibition, performance and event to raise awareness.